Wealth Preservation Advisors’s Travere Therapeutics TVTX Stock Holding History

Wealth Preservation Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.75K	Buy	+59	New	+$1.76K	﹤0.01%	610

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wealth Preservation Advisors's TVTX Position: Q1 2026 in Review

Wealth Preservation Advisors opened a new position in Travere Therapeutics (TVTX) in Q1 2026: 59 shares worth $1.75K. The stake represents ﹤0.01% of the portfolio and ranks #610 among its holdings.

260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

Wealth Preservation Advisors held 59 shares of Travere Therapeutics worth $1.75K as of Q1 2026.
Travere Therapeutics was a new Wealth Preservation Advisors position in Q1 2026.
Travere Therapeutics made up ﹤0.01% of Wealth Preservation Advisors's portfolio in Q1 2026, its #610 holding.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Wealth Preservation Advisors's 13F filing for Q1 2026, filed 15 May 2026.